BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matthews PM. Chronic inflammation in multiple sclerosis - seeing what was always there. Nat Rev Neurol. 2019;15:582-593. [PMID: 31420598 DOI: 10.1038/s41582-019-0240-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Haacke EM, Ge Y, Sethi SK, Buch S, Zamboni P. An Overview of Venous Abnormalities Related to the Development of Lesions in Multiple Sclerosis. Front Neurol 2021;12:561458. [PMID: 33981281 DOI: 10.3389/fneur.2021.561458] [Reference Citation Analysis]
2 Rayatpour A, Farhangi S, Verdaguer E, Olloquequi J, Ureña J, Auladell C, Javan M. The Cross Talk between Underlying Mechanisms of Multiple Sclerosis and Epilepsy May Provide New Insights for More Efficient Therapies. Pharmaceuticals (Basel) 2021;14:1031. [PMID: 34681255 DOI: 10.3390/ph14101031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Skok M. Mesenchymal stem cells as a potential therapeutic tool to cure cognitive impairment caused by neuroinflammation. World J Stem Cells 2021; 13(8): 1072-1083 [PMID: 34567426 DOI: 10.4252/wjsc.v13.i8.1072] [Reference Citation Analysis]
4 Gil-Martins E, Barbosa DJ, Silva V, Remião F, Silva R. Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders. Pharmacol Ther 2020;213:107554. [PMID: 32320731 DOI: 10.1016/j.pharmthera.2020.107554] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
5 Kuchling J, Paul F. Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Front Neurol 2020;11:450. [PMID: 32625158 DOI: 10.3389/fneur.2020.00450] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
6 Bodini B, Tonietto M, Airas L, Stankoff B. Positron emission tomography in multiple sclerosis - straight to the target. Nat Rev Neurol 2021;17:663-75. [PMID: 34545219 DOI: 10.1038/s41582-021-00537-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ng Kee Kwong KC, Mollison D, Meijboom R, York EN, Kampaite A, Thrippleton MJ, Chandran S, Waldman AD. The prevalence of paramagnetic rim lesions in multiple sclerosis: A systematic review and meta-analysis. PLoS One 2021;16:e0256845. [PMID: 34495999 DOI: 10.1371/journal.pone.0256845] [Reference Citation Analysis]
8 Ramírez Hernández E, Sánchez-Maldonado C, Mayoral Chávez MA, Hernández-Zimbrón LF, Patricio Martínez A, Zenteno E, Limón Pérez de León ID. The therapeutic potential of galectin-1 and galectin-3 in the treatment of neurodegenerative diseases. Expert Rev Neurother 2020;20:439-48. [PMID: 32303136 DOI: 10.1080/14737175.2020.1750955] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
9 Sánchez-Fernández A, Zandee S, Amo-Aparicio J, Charabati M, Prat A, Garlanda C, Eisenmesser EZ, Dinarello CA, López-Vales R. IL-37 exerts therapeutic effects in experimental autoimmune encephalomyelitis through the receptor complex IL-1R5/IL-1R8. Theranostics 2021;11:1-13. [PMID: 33391457 DOI: 10.7150/thno.47435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Piec PA, Pons V, Rivest S. Triggering Innate Immune Receptors as New Therapies in Alzheimer's Disease and Multiple Sclerosis. Cells 2021;10:2164. [PMID: 34440933 DOI: 10.3390/cells10082164] [Reference Citation Analysis]
11 Cree BAC, Arnold DL, Chataway J, Chitnis T, Fox RJ, Pozo Ramajo A, Murphy N, Lassmann H. Secondary Progressive Multiple Sclerosis: New Insights. Neurology 2021;97:378-88. [PMID: 34088878 DOI: 10.1212/WNL.0000000000012323] [Reference Citation Analysis]
12 Sun H, Yang H, Wu Y, Bian H, Wang M, Huang Y, Jin J. iRhom1 rescues cognitive dysfunction in multiple sclerosis via preventing myelin injury. Genes Brain Behav 2021;20:e12771. [PMID: 34672089 DOI: 10.1111/gbb.12771] [Reference Citation Analysis]
13 Villoslada P, Steinman L. New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis. Expert Opinion on Investigational Drugs 2020;29:443-59. [DOI: 10.1080/13543784.2020.1757647] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
14 Voo VTF, Butzkueven H, Stankovich J, O'Brien T, Monif M. The development and impact of cladribine on lymphoid and myeloid cells in multiple sclerosis. Mult Scler Relat Disord 2021;52:102962. [PMID: 33901971 DOI: 10.1016/j.msard.2021.102962] [Reference Citation Analysis]
15 Long MJC, Miranda Herrera PA, Aye Y. Hitting the Bullseye: Endogenous Electrophiles Show Remarkable Nuance in Signaling Regulation. Chem Res Toxicol 2022. [PMID: 35394758 DOI: 10.1021/acs.chemrestox.2c00006] [Reference Citation Analysis]
16 Ye H, Shaghaghi M, Chen Q, Zhang Y, Lutz SE, Chen W, Cai K. In Vivo Proton Exchange Rate (kex ) MRI for the Characterization of Multiple Sclerosis Lesions in Patients. J Magn Reson Imaging 2021;53:408-15. [PMID: 32975008 DOI: 10.1002/jmri.27363] [Reference Citation Analysis]
17 Li J, Zheng M, Shimoni O, Banks WA, Bush AI, Gamble JR, Shi B. Development of Novel Therapeutics Targeting the Blood-Brain Barrier: From Barrier to Carrier. Adv Sci (Weinh) 2021;:e2101090. [PMID: 34085418 DOI: 10.1002/advs.202101090] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
18 Mahler C, Schumacher AM, Unterrainer M, Kaiser L, Höllbacher T, Lindner S, Havla J, Ertl-Wagner B, Patzig M, Seelos K, Neitzel J, Mäurer M, Krumbholz M, Metz I, Brück W, Stadelmann C, Merkler D, Gass A, Milenkovic V, Bartenstein P, Albert NL, Kümpfel T, Kerschensteiner M. TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy. Brain 2021:awab127. [PMID: 33757118 DOI: 10.1093/brain/awab127] [Reference Citation Analysis]
19 Sidoryk-Węgrzynowicz M, Dąbrowska-Bouta B, Sulkowski G, Strużyńska L. Nanosystems and exosomes as future approaches in treating multiple sclerosis. Eur J Neurosci 2021;54:7377-404. [PMID: 34561918 DOI: 10.1111/ejn.15478] [Reference Citation Analysis]
20 Diaz-Castro B, Bernstein AM, Coppola G, Sofroniew MV, Khakh BS. Molecular and functional properties of cortical astrocytes during peripherally induced neuroinflammation. Cell Rep 2021;36:109508. [PMID: 34380036 DOI: 10.1016/j.celrep.2021.109508] [Reference Citation Analysis]
21 Siger M. Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients : Review. Clin Neuroradiol 2022. [PMID: 35258820 DOI: 10.1007/s00062-022-01144-3] [Reference Citation Analysis]
22 Noguera-navarro C, Navas-carrillo D, Orenes-piñero E. Gut microbiota alterations and nutritional intervention in multiple sclerosis disease. Food Reviews International. [DOI: 10.1080/87559129.2022.2062771] [Reference Citation Analysis]
23 Yeung SS, Ho YS, Chang RC. The role of meningeal populations of type II innate lymphoid cells in modulating neuroinflammation in neurodegenerative diseases. Exp Mol Med 2021;53:1251-67. [PMID: 34489558 DOI: 10.1038/s12276-021-00660-5] [Reference Citation Analysis]
24 Tsaktanis T, Beyer T, Nirschl L, Linnerbauer M, Grummel V, Bussas M, Tjon E, Mühlau M, Korn T, Hemmer B, Quintana FJ, Rothhammer V. Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS. Neurol Neuroimmunol Neuroinflamm 2021;8:e933. [PMID: 33361385 DOI: 10.1212/NXI.0000000000000933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Gafson AR, Barthélemy NR, Bomont P, Carare RO, Durham HD, Julien JP, Kuhle J, Leppert D, Nixon RA, Weller RO, Zetterberg H, Matthews PM. Neurofilaments: neurobiological foundations for biomarker applications. Brain 2020;143:1975-98. [PMID: 32408345 DOI: 10.1093/brain/awaa098] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 16.0] [Reference Citation Analysis]
26 Poganik JR, Huang KT, Parvez S, Zhao Y, Raja S, Long MJC, Aye Y. Wdr1 and cofilin are necessary mediators of immune-cell-specific apoptosis triggered by Tecfidera. Nat Commun 2021;12:5736. [PMID: 34593792 DOI: 10.1038/s41467-021-25466-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Wu J, Tang Y. Revisiting the Immune Balance Theory: A Neurological Insight Into the Epidemic of COVID-19 and Its Alike. Front Neurol 2020;11:566680. [PMID: 33178109 DOI: 10.3389/fneur.2020.566680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Anderson S, Grist JT, Lewis A, Tyler DJ. Hyperpolarized 13 C magnetic resonance imaging for noninvasive assessment of tissue inflammation. NMR Biomed 2021;34:e4460. [PMID: 33291188 DOI: 10.1002/nbm.4460] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Watts JJ, Garani R, Da Silva T, Lalang N, Chavez S, Mizrahi R. Evidence That Cannabis Exposure, Abuse, and Dependence Are Related to Glutamate Metabolism and Glial Function in the Anterior Cingulate Cortex: A 1H-Magnetic Resonance Spectroscopy Study. Front Psychiatry 2020;11:764. [PMID: 32973572 DOI: 10.3389/fpsyt.2020.00764] [Reference Citation Analysis]
30 Deshaies RJ. Multispecific drugs herald a new era of biopharmaceutical innovation. Nature 2020;580:329-38. [DOI: 10.1038/s41586-020-2168-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 29.0] [Reference Citation Analysis]
31 Mosxou D, Letsiou S. Exploring the Protective Effects of Phaeodactylum tricornutum Extract on LPS-Treated Fibroblasts. Cosmetics 2021;8:76. [DOI: 10.3390/cosmetics8030076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Kordulewska N, Topa J, Cieślińska A, Jarmołowska B. Osthole Regulates Secretion of Pro-Inflammatory Cytokines and Expression of TLR2 and NF-κB in Normal Human Keratinocytes and Fibroblasts. JIR 2022;Volume 15:1501-19. [DOI: 10.2147/jir.s349216] [Reference Citation Analysis]
33 Zhang J, Du Q, Song X, Gao S, Pang X, Li Y, Zhang R, Abliz Z, He J. Evaluation of the tumor-targeting efficiency and intratumor heterogeneity of anticancer drugs using quantitative mass spectrometry imaging. Theranostics 2020;10:2621-30. [PMID: 32194824 DOI: 10.7150/thno.41763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Sidoryk-Węgrzynowicz M, Strużyńska L. Astroglial and Microglial Purinergic P2X7 Receptor as a Major Contributor to Neuroinflammation during the Course of Multiple Sclerosis. Int J Mol Sci 2021;22:8404. [PMID: 34445109 DOI: 10.3390/ijms22168404] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Lorenzini L, Fernandez M, Baldassarro VA, Bighinati A, Giuliani A, Calzà L, Giardino L. White Matter and Neuroprotection in Alzheimer's Dementia. Molecules 2020;25:E503. [PMID: 31979414 DOI: 10.3390/molecules25030503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
36 Mennecke AB, Nagel AM, Huhn K, Linker RA, Schmidt M, Rothhammer V, Wilferth T, Linz P, Wegmann J, Eisenhut F, Engelhorn T, Doerfler A. Longitudinal Sodium MRI of Multiple Sclerosis Lesions: Is there Added Value of Sodium Inversion Recovery MRI. J Magn Reson Imaging 2021. [PMID: 34259373 DOI: 10.1002/jmri.27832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Fernandes EFA, Özcelik D. Imaging Biomarkers for Monitoring the Inflammatory Redox Landscape in the Brain. Antioxidants (Basel) 2021;10:528. [PMID: 33800685 DOI: 10.3390/antiox10040528] [Reference Citation Analysis]
38 Reyes S, Smets I, Holden D, Carrillo-Loza K, Christmas T, Bianchi L, Ammoscato F, Turner B, Marta M, Schmierer K, Giovannoni G, Gnanapavan S. CSF neurofilament light chain testing as an aid to determine treatment strategies in MS. Neurol Neuroimmunol Neuroinflamm 2020;7:e880. [PMID: 32826298 DOI: 10.1212/NXI.0000000000000880] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
39 Kamma E, Lasisi W, Libner C, Ng HS, Plemel JR. Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics. J Neuroinflammation 2022;19:45. [PMID: 35144628 DOI: 10.1186/s12974-022-02408-y] [Reference Citation Analysis]